Method effector cells using anti-CD127 antibodies for applications in cell therapy
US12258577B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 29, 2018 |
| Grant date | Mar 25, 2025 |
| Priority date | — |
| Expiry date | Dec 16, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N5/0636
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods and preparations for sorting out T effector cells from human leukocytes using anti-CD127 antibodies. Accordingly the invention relates to the use of anti-CD127 antibodies enabling discriminative depletion of subpopulations of Tregulatory cells expressing CD127+ at low levels in a population of human T lymphocytes in order to enable the use of the recovered selected cell preparations comprising essentially Teffector cells as lymphocytes and preferably devoid of Tregulatory cells, for improved efficacy in particular when administered to a patient for therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.